high-risk

2:33
Treatment options for high-risk myeloma
Annemiek Broyl
1:56
How do we define a ‘cure’ in myeloma?
Annemiek Broyl
2:48
MRD and disease eradication in myeloma
Jesús San Miguel
1:59
Smoldering multiple myeloma: what is the current definition & new screening programme
Irene Ghobrial
2:32
Improving the treatment landscape for DLBCL patients
Andrés Ferreri
2:14
How to define and treat high-risk lymphoma
Andrés Ferreri
1:58
Logistics for a technique to avoid GvHD
Denis Claude Roy
1:56
Implications for a technique which eliminates GvHD
Denis Claude Roy
2:08
Eradicating GvHD after haploidentical stem cell transplant
Denis Claude Roy
1:05
When is the use of MRD appropriate?
Rafael Fonseca
1:06
Response to MM therapy can vary based on a variety of factors
Shaji Kumar
3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trneny
3:17
Improving outcomes after transplant in AML
Charles Craddock
3:02
New technologies informing SOC in DLBCL
Christian Gisselbrecht
1:25
Bringing CAR T-cells to the second-line setting
Jeremy Abramson
1:54
FORTE update: carfilzomib-lenalidomide induction therapy for MM
Francesca Gay
The content of VJHemOnc is intended for healthcare professionals